Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply

Ines Pires da Silva; Tasnia Ahmed; Irene L.M. Reijers; Allison Betof Warner; James Randall Patrinely; Patricio Serra-Bellver; Clara Allayous; Joanna Mangana; Lisa Zimmer; Claudia Trojaniello; Oliver Klein; Camille L. Gerard; Olivier Michielin; Andrew Haydon; Paolo A. Ascierto; Matteo S. Carlino; Celeste Lebbe; Paul Lorigan; Douglas B. Johnson; Shahneen Sandhu; Serigne N. Lo; Alexander M. Menzies; Georgina V. Long

doi:10.1016/S1470-2045(21)00419-8

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply

Ines Pires da Silva, Tasnia Ahmed, Irene L.M. Reijers, Allison Betof Warner, James Randall Patrinely, Patricio Serra-Bellver, Clara Allayous, Joanna Mangana, Lisa Zimmer, Claudia Trojaniello, Oliver Klein, Camille L. Gerard, Olivier Michielin, Andrew Haydon, Paolo A. Ascierto, Matteo S. Carlino, Celeste Lebbe, Paul Lorigan, Douglas B. Johnson, Shahneen SandhuSerigne N. Lo, Alexander M. Menzies, Georgina V. Long

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e343-e344
Journal	The Lancet Oncology
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/S1470-2045(21)00419-8
Publication status	Published - Aug 2021

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(21)00419-8

Cite this

da Silva, I. P., Ahmed, T., Reijers, I. L. M., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Zimmer, L., Trojaniello, C., Klein, O., Gerard, C. L., Michielin, O., Haydon, A., Ascierto, P. A., Carlino, M. S., Lebbe, C., Lorigan, P., Johnson, D. B., ... Long, G. V. (2021). Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. The Lancet Oncology, 22(8), e343-e344. https://doi.org/10.1016/S1470-2045(21)00419-8

@article{a7420215273647d8b2011e496ac5b3e8,

title = "Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply",

author = "{da Silva}, {Ines Pires} and Tasnia Ahmed and Reijers, {Irene L.M.} and Warner, {Allison Betof} and Patrinely, {James Randall} and Patricio Serra-Bellver and Clara Allayous and Joanna Mangana and Lisa Zimmer and Claudia Trojaniello and Oliver Klein and Gerard, {Camille L.} and Olivier Michielin and Andrew Haydon and Ascierto, {Paolo A.} and Carlino, {Matteo S.} and Celeste Lebbe and Paul Lorigan and Johnson, {Douglas B.} and Shahneen Sandhu and Lo, {Serigne N.} and Menzies, {Alexander M.} and Long, {Georgina V.}",

note = "Funding Information: IPdS reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, and Roche, outside the submitted work. ABW reports personal fees from Shanghai Jo{\textquoteright}Ann Medical Technology, Nanobiotix, Novartis, LG Chem Life Sciences, and Iovance, outside the submitted work. CA reports personal fees from Roche, Amgen, and Bristol Myers Squibb, outside the submitted work. JM reports grants, personal fees, and travel grants from Bristol Myers Squibb and Merck Sharp & Dohme; personal fees from Merck Sharp & Dohme, Pfizer, Sanofi, Amgen, and Novartis; personal fees and travel grants from Pierre Fabre; and travel grants from Ultrasun and Loreal, outside the submitted work. LZ reports personal fees, advisory board participation, and travel grants from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Roche, and Novartis; and advisory board participation and travel grants from Sanofi and Amgen, outside the submitted work. OK and AH report personal fees from Bristol Myers Squibb and Merck Sharp & Dohme, outside the submitted work. OM reports grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre-Fabre, and Amgen; personal fees from Roche, Novartis, and GlaxoSmithKline; and grants from Merck Sharp & Dohme, outside the submitted work. PAA reports grants and personal fees from Bristol Myers Squibb, Roche, Array BioPharma, and Sanofi; personal fees from Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, and Lunaphore; and uncompensated consultant service from Takis, outside the submitted work. MSC reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Sanofi, Merck Serono, Pierre Fabre, Roche, Ideaya, Regeneron, Nektar, Eisai, Qbiotics, and Oncosec, outside the submitted work. CL reports grants and personal fees from Bristol Myers Squibb and Roche; personal fees from Merck Sharp & Dohme, Novartis, Amgen, Avantis Medical Systems, Pierre Fabre, Pfizer, Incyte, Merck Serono, and Sanofi, outside the submitted work. PL reports personal fees and support for travel from Merck Sharp & Dohme and Novartis; personal fees from Amgen, Nektar, and Pierre Fabre; and grants, personal fees, and support for travel from Bristol Myers Squibb, outside the submitted work. DBJ reports being part of advisory boards and consulting for Array Biopharma, Catalyst, Iovance, Jansen, Merck Sharp & Dohme, Novartis, and Oncosec; grants and other research funding from Bristol Myers Squibb; and grants from Incyte, outside the submitted work. SS reports grants from Novartis, AstraZeneca, Merck Sharp & Dohme, and Genentech; and personal fees from AstraZeneca, Merck Sharp & Dohme, and Bristol Myers Squibb, outside the submitted work. AMM reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and QBiotics, outside the submitted work. GVL reports personal fees from Amgen, Array Biopharma, Boehringer Ingelheim, Bristol Myers Squibb, Hexal, Highlight Therapeutics, Merck Sharp & Dohme, Novartis, Pierre Fabre, QBiotics, Regeneron Pharmaceuticals, and Specialised Therapeutics Australia, outside the submitted work. All other authors declare no competing interests.",

year = "2021",

month = aug,

doi = "10.1016/S1470-2045(21)00419-8",

language = "English",

volume = "22",

pages = "e343--e344",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier BV",

number = "8",

}

da Silva, IP, Ahmed, T, Reijers, ILM, Warner, AB, Patrinely, JR, Serra-Bellver, P, Allayous, C, Mangana, J, Zimmer, L, Trojaniello, C, Klein, O, Gerard, CL, Michielin, O, Haydon, A, Ascierto, PA, Carlino, MS, Lebbe, C, Lorigan, P, Johnson, DB, Sandhu, S, Lo, SN, Menzies, AM & Long, GV 2021, 'Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply', The Lancet Oncology, vol. 22, no. 8, pp. e343-e344. https://doi.org/10.1016/S1470-2045(21)00419-8

TY - JOUR

T1 - Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply

AU - da Silva, Ines Pires

AU - Ahmed, Tasnia

AU - Reijers, Irene L.M.

AU - Warner, Allison Betof

AU - Patrinely, James Randall

AU - Serra-Bellver, Patricio

AU - Allayous, Clara

AU - Mangana, Joanna

AU - Zimmer, Lisa

AU - Trojaniello, Claudia

AU - Klein, Oliver

AU - Gerard, Camille L.

AU - Michielin, Olivier

AU - Haydon, Andrew

AU - Ascierto, Paolo A.

AU - Carlino, Matteo S.

AU - Lebbe, Celeste

AU - Lorigan, Paul

AU - Johnson, Douglas B.

AU - Sandhu, Shahneen

AU - Lo, Serigne N.

AU - Menzies, Alexander M.

AU - Long, Georgina V.

N1 - Funding Information: IPdS reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, and Roche, outside the submitted work. ABW reports personal fees from Shanghai Jo’Ann Medical Technology, Nanobiotix, Novartis, LG Chem Life Sciences, and Iovance, outside the submitted work. CA reports personal fees from Roche, Amgen, and Bristol Myers Squibb, outside the submitted work. JM reports grants, personal fees, and travel grants from Bristol Myers Squibb and Merck Sharp & Dohme; personal fees from Merck Sharp & Dohme, Pfizer, Sanofi, Amgen, and Novartis; personal fees and travel grants from Pierre Fabre; and travel grants from Ultrasun and Loreal, outside the submitted work. LZ reports personal fees, advisory board participation, and travel grants from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre Fabre, Roche, and Novartis; and advisory board participation and travel grants from Sanofi and Amgen, outside the submitted work. OK and AH report personal fees from Bristol Myers Squibb and Merck Sharp & Dohme, outside the submitted work. OM reports grants and personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Pierre-Fabre, and Amgen; personal fees from Roche, Novartis, and GlaxoSmithKline; and grants from Merck Sharp & Dohme, outside the submitted work. PAA reports grants and personal fees from Bristol Myers Squibb, Roche, Array BioPharma, and Sanofi; personal fees from Merck Sharp & Dohme, Novartis, Merck Serono, Pierre Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, and Lunaphore; and uncompensated consultant service from Takis, outside the submitted work. MSC reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Amgen, Sanofi, Merck Serono, Pierre Fabre, Roche, Ideaya, Regeneron, Nektar, Eisai, Qbiotics, and Oncosec, outside the submitted work. CL reports grants and personal fees from Bristol Myers Squibb and Roche; personal fees from Merck Sharp & Dohme, Novartis, Amgen, Avantis Medical Systems, Pierre Fabre, Pfizer, Incyte, Merck Serono, and Sanofi, outside the submitted work. PL reports personal fees and support for travel from Merck Sharp & Dohme and Novartis; personal fees from Amgen, Nektar, and Pierre Fabre; and grants, personal fees, and support for travel from Bristol Myers Squibb, outside the submitted work. DBJ reports being part of advisory boards and consulting for Array Biopharma, Catalyst, Iovance, Jansen, Merck Sharp & Dohme, Novartis, and Oncosec; grants and other research funding from Bristol Myers Squibb; and grants from Incyte, outside the submitted work. SS reports grants from Novartis, AstraZeneca, Merck Sharp & Dohme, and Genentech; and personal fees from AstraZeneca, Merck Sharp & Dohme, and Bristol Myers Squibb, outside the submitted work. AMM reports personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Pierre Fabre, and QBiotics, outside the submitted work. GVL reports personal fees from Amgen, Array Biopharma, Boehringer Ingelheim, Bristol Myers Squibb, Hexal, Highlight Therapeutics, Merck Sharp & Dohme, Novartis, Pierre Fabre, QBiotics, Regeneron Pharmaceuticals, and Specialised Therapeutics Australia, outside the submitted work. All other authors declare no competing interests.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85111477984&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(21)00419-8

DO - 10.1016/S1470-2045(21)00419-8

M3 - Letter

C2 - 34339647

AN - SCOPUS:85111477984

SN - 1470-2045

VL - 22

SP - e343-e344

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 8

ER -

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Cite this